Should I Say Adios to Dexcom G7, Hello Abbott Freestyle Libre 2? Maybe.

ConclusionIn the end, I ' m getting sick of Dexcom and its product. I feel as if the company ' s initial focus on patients has declined, and the company now takes its patients for granted as it pushes for events to drive its share price up, and while its retail model has made getting the product to consumers vastly easier, but its basic product has not improved much. The new G7 model will make some modest changes, along with reducing the number of SKU ' s needed for the company to commercialize the product, which is less of a patient benefit and more about making distribution to retail pharmacies easier for the company. That should theoretically result in lower prices, but because it combines sensor and transmitter functions into a single item, patients can basically count on higher prices. That means Dexcom views patients as little more than a revenue source. Is that really worth a slightly shorter warm-up? That depends on if it fixes the countless problems I ' ve experienced over the past few years with " Signal Loss " and calibrations being rejected. Sorry, but I trust fingerstick readings much more than I do CGM interstitial fluid correlations. If Dexcom fixes those problems, I ' ll be pleased. These things have me seriously considering alternatives to Dexcom. And Abbott ' s Freestyle Libre 2 is one of them I ' m considering because of its simplicity and add-on functionality. Then again, the Libre 3 model could be commercialized before too long. Watch this space.
Source: Scott's Web Log - Category: Endocrinology Tags: Abbott CGM CGMS continuous glucose monitor Dexcom Freestyle Libre Source Type: blogs